Étiquette : interaction CBD/THC

Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease : the EMERALD trial, Berzenn Urbi et al., 2019,

Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease progression of Amyotrophic Lateral sclerosis or motor neurone Disease : the EMERALD trial Berzenn Urbi, Simon Broadley, Richard Bedlack, Ethan Russo, Arman Sabet British Medical Journal Open, 2019, 9, e029449. doi : 10.1136/bmjopen-2019-029449   Abstract Introduction : Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder with no known cure and with an average life expectancy of 3–5 years post diagnosis. The use of complementary medicine such as medicinal cannabis in search for a potential treatment or cure is common in ALS. Preclinical studies have demonstrated the efficacy [...]

Lire la suite

Cannabidiol Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral Hippocampus Through Bi-Directional Control of ERK1-2 Phosphorylation, Roger Hudson et al., 2019

Cannabidiol Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral Hippocampus Through Bi-Directional Control of ERK1-2 Phosphorylation Roger Hudson, Justine Renard, Christopher Norris, Walter J. Rushlow and Steven R. Laviolette The Journal of Neuroscience, 2019 https://doi.org/10.1523/JNEUROSCI.0708-19.2019   Abstract Evidence suggests that the phytocannabinoids Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) differentially regulate salience attribution and psychiatric risk. The ventral hippocampus (vHipp) relays emotional salience via control of dopamine (DA) neuronal activity states, which are dysregulated in psychosis and schizophrenia. Using in-vivo electrophysiology in male Sprague Dawley rats, we demonstrate that intra-vHipp THC strongly increases ventral tegmental area (VTA) DA neuronal frequency and bursting rates, decreases GABA frequency, and [...]

Lire la suite

CBD Isolates Vs. Full-Spectrum CBD, Martin A. LEE, projectCBD.org, 2015

CBD Isolates Vs. Full-Spectrum CBD Martin A. Lee On February 22, 2015 https://www.projectcbd.org/science/cbd-isolates-vs-full-spectrum-cbd A groundbreaking study has documented the superior therapeutic properties of whole plant CBD-rich cannabis extract as compared to single-molecule CBD.   A groundbreaking study from Israel has documented the superior therapeutic properties of whole plant CBD-rich cannabis extract as compared to single-molecule cannabidiol (CBD). Published in the journal Pharmacology & Pharmacy (Feb. 2015), the article directly challenges one of the sacred cows of Big Pharma and the medical-industrial complex—the notion that “crude” botanical preparations are inherently low grade and less effective than pure, single-molecule compounds. Entitled “Overcoming the Bell-Shaped Dose-Response of Cannabidiol by Using Cannabis [...]

Lire la suite

CBD : The Cinderella Molecule, Martin A. LEE, projectCBD.org, 2017

CBD : The Cinderella Molecule Martin A. Lee On February 09, 2017 Originally published in High Times (Feb. 2017) https://www.projectcbd.org/culture/cbd-cinderella-molecule High Times cover story by Martin A Lee highlights the breakthrough research on CBD, and how it has revolutionized the story of cannabis medicine. “This changes everything!” That was the immediate reaction of Bay Area journalist Fred Gardner as he stood in the office of Steep Hill Laboratory in Oakland and eyed a chromatogram showing the unusual cannabinoid content of a hitherto unknown marijuana strain. The year was 2009, and the strain of interest, an oddity called Soma A-Plus, didn’t top the charts with THC (tetrahydrocannabinol), [...]

Lire la suite

CBD User’s Guide, ProjectCBD.org, 2019

CBD User's Guide Project CBD On March 13, 2018 (Updated on March 25, 2019) https://www.projectcbd.org/how-to/cbd-users-guide   Project CBD has created a beginner’s guide for cannabidiol & cannabis therapeutics to address key questions of CBD users. A Beginner’s Guide to CBD & Cannabis Therapeutics   In 2009, a handful of CBD-rich cannabis strains were discovered serendipitously in Northern California, America’s cannabis breadbasket, where certified patients could access medical marijuana legally. Thus began a great laboratory experiment in democracy involving CBD-rich cannabis therapeutics. The advent of whole plant CBD-rich oil as a grassroots therapeutic option has changed the national conversation about cannabis. It’s no longer a question of whether [...]

Lire la suite

Acceptance of pharmaceutical cannabis substitution by cannabis using patients with schizophrenia, Jan van Amsterdam et al., 2018

Acceptance of pharmaceutical cannabis substitution by cannabis using patients with schizophrenia Jan van Amsterdam, Jojanneke Vervloet, Gerdien de Weert, Victor J. A. Buwalda, Anna E. Goudriaan and Wim van den Brink Harm Reduction Journal, 2018, 15, 47, 1-4. Doi : 10.1186/s12954-018-0253-7   Abstract Background : Cannabis-smoking patients with a psychotic disorder have poorer disease outcomes than non-cannabis-smoking patients with poorest outcomes in patients smoking high-potency cannabis (HPC) containing high Δ9-tetrahydrocannabinol (THC) and low cannabidiol (CBD). Quitting cannabis smoking or substitution of HPC by cannabis variants containing less THC and/or more CBD may benefit these patients. The present study explores whether daily HPC-smoking patients with schizophrenia accept smoking [...]

Lire la suite

Using CBD to tame a cannabis high? Small doses may have opposite effect, Bailey Rahn, 2019

Using CBD to tame a cannabis high? Small doses may have opposite effect Bailey Rahn February 28, 2019   Share   Print (imaginima/iStock) Take some CBD, they said. You’ll feel less high, they said. This common piece of advice fed to THC-shy consumers can effectively bring someone back down to earth. It works—sometimes. But new research shows there’s likely more nuance in the solution than we initially thought. Scientists found that a high dose of CBD dampened the effects of a THC high, but participants reported a stronger high when combined with low doses of CBD. CBD can either dampen an out-of-control high [...]

Lire la suite

Cannabinoids for the treatment of mental disorders and symptoms of mental disorders : a systematic review and meta-analysis, Nicola Black et al., 2019,

Cannabinoids for the treatment of mental disorders and symptoms of mental disorders : a systematic review and meta-analysis Nicola Black, Emily Stockings, Gabrielle Campbell, Lucy T. Tran, Dino Zagic, Wayne D. Hall, Michael Farrell, Louisa Degenhardt Lancet Psychiatry, 2019 https://doi.org/10.1016/S2215-0366(19)30401-8   Summary Background : Medicinal cannabinoids, including medicinal cannabis and pharmaceutical cannabinoids and their synthetic derivatives, such as tetrahydrocannabinol (THC) and cannabidiol (CBD), have been suggested to have a therapeutic role in certain mental disorders. We analysed the available evidence to ascertain the effectiveness and safety of all types of medicinal cannabinoids in treating symptoms of various mental disorders. Methods : For this systematic review and meta-analysis [...]

Lire la suite

Cannabidiol Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral Hippocampus through Bidirectional Control of ERK1–2 Phosphorylation, Roger Hudson et al., 2019

Cannabidiol Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral Hippocampus through Bidirectional Control of ERK1–2 Phosphorylation Roger Hudson, Justine Renard, Christopher Norris, Walter J. Rushlow and Steven R. Laviolette Journal of Neuroscience, 2019, 39, (44), 8762-8777 Doi : https://doi.org/10.1523/JNEUROSCI.0708-19.2019   Abstract Evidence suggests that the phytocannabinoids Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) differentially regulate salience attribution and psychiatric risk. The ventral hippocampus (vHipp) relays emotional salience via control of dopamine (DA) neuronal activity states, which are dysregulated in psychosis and schizophrenia. Using in vivo electrophysiology in male Sprague Dawley rats, we demonstrate that intra-vHipp THC strongly increases ventral tegmental area (VTA) DA neuronal frequency [...]

Lire la suite

Dosage Related Efficacy and Tolerability of Cannabidiol in Children With Treatment-Resistant Epileptic Encephalopathy : Preliminary Results of the CARE-E Study, Richard J. Huntsman et al., 2019

Dosage Related Efficacy and Tolerability of Cannabidiol in Children With Treatment-Resistant Epileptic Encephalopathy : Preliminary Results of the CARE-E Study Richard J. Huntsman, Richard Tang-Wai, Jane Alcorn, Stephanie Vuong, Bryan Acton1,5, Scott Corley, Robert Laprairie, Andrew W. Lyon, Simona Meier, Darrell D. Mousseau, Doris Newmeyer, Erin Prosser-Loose, Blair Seifert, Jose Tellez-Zenteno, Linda Huh, Edward Leung and Philippe Major Frontiers in  Neurology, 2019, 10:716. doi: 10.3389/fneur.2019.00716   Purpose : There is uncertainty regarding the appropriate dose of Cannabidiol (CBD) for childhood epilepsy. We present the preliminary data of seven participants from the Cannabidiol in Children with Refractory Epileptic Encephalopathy (CARE-E) study. Methods : The study is an open-label, [...]

Lire la suite